Rexam Healthcare receives Lilly award

2010 Lilly Global Supplier Award recognises positive impact made on quality, speed and service

Rexam Healthcare, a global leader in healthcare packaging and devices, has been awarded a 2010 Lilly Global Supplier Award in recognition of its positive impact on Lilly in the areas of quality, speed, service and cost reduction.

‘We have demonstrated our capacity to manage a large-scale industrial project in close partnership with Lilly and to create value with high-quality solutions and support services, for the entire benefit of diabetic patients throughout the world,’ said Marc Haemel, managing director of Rexam Healthcare.

‘We are proud of our teams for this achievement and will strive to improve further the value we bring to Lilly.’

You may also like

Manufacturing

Nemera extends manufacturing capabilities in North America

With a newly acquired space in Vernon Hills, Nemera has opened a third location in the US, in addition to the manufacturing facility in Buffalo Grove and Innovation Center in Chicago
Manufacturing

Lilly set to acquire Versanis Bio to "improve patient outcomes in cardiometabolic diseases"

Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash
Research & Development

Lilly and ProQR to expand RNA editing collaboration

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilising ProQR’s Axiomer technology
Finance

Nemera to build drug delivery device facility in Poland

The production plant is being built on an area of 5 hectares with dedicated expandable clean room space
Finance

Nemera to acquire Copernicus

The acquisition establishes Nemera’s operations footprint in Eastern Europe.
Ingredients

Eli Lilly comments on supply chain safety during outbreak

US-based Eli Lilly and Company has issued a statement today regarding the novel coronavirus' impact on insulin and other products
Finance

Eli Lilly makes $1.1bn biopharma acquisition

Pharma giant Eli Lilly has agreed to acquire chronic skin condition-focused biopharma Dermira
Subscribe now